If you have been reading about Mod GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-31. Numbers and descriptions here follow the published literature rather than marketing material.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
=== Non-neuronal Control === Non-neuronal control has been found to be indirect paracrine regulation through ions, hormones, and neurotransmitters. Zinc, insulin, serotonin, γ-aminobutyric acid, and γ-hydroxybutyrate, all of which are released by beta cells in the pancreas, have been found to suppress glucagon production in alpha cells. Delta cells also release somatostatin which has been found to inhibit glucagon secretion. Zinc is secreted at the same time as insulin by the beta cells in the pancreas. It has been proposed to act as a paracrine signal to inhibit glucagon secretion in alpha cells. Zinc is transported into both alpha and beta cells by the zinc transporter ZnT8. This protein channel allows zinc to cross the plasma membrane into the cell. When ZnT8 is under-expressed, there is a marked increase in glucagon secretion. When ZnT8 is over-expressed, there is a marked decrease in glucagon secretion. The exact mechanism by which zinc inhibits glucagon secretion is not known. Insulin has been shown to function as a paracrine signal to inhibit glucagon secretion by the alpha cells. However, this is not through a direct interaction. It appears that insulin functions to inhibit glucagon secretion through activation of delta cells to secrete somatostatin. Insulin binds to SGLT2 causing an increased glucose uptake into delta cells. SGLT2 is a sodium and glucose symporter, meaning that it brings glucose and sodium ions across the membrane at the same time in the same direction.
=== Cobalt-catalyzed routes === Related to the nickel-catalyzed alkyne trimerization, several methods have been developed using organocobalt compounds as catalysts. The organic precursors include acetonitrile, acetylene, and acrylonitrile.
==== Saline breast prosthesis ==== The first commercial model of a breast prosthesis filled with saline solution was made by Laboratoires Arion of France, which they publicly presented as a prosthetic medical device in 1964. The modern models of prosthetic breasts filled saline-solution are made with vulcanized shells composed of a silicone elastomer of great elasticity, like that of the skin and tissues of a woman's breast. In an augmentation mammoplasty to emplace a saline breast-prosthesis, the plastic surgeon employs a short incision to the chest wall, through that incision the surgeon then inserts the collapsed, empty prosthetic breast into the breast-implant socket, then fills the implanted breast prosthesis with saline solution. The surgeon then contours the implanted prosthetic breast for anatomical symmetry, and afterwards sutures shut the insertion incision. Functionally, the implantation of a saline breast-prosthesis yields good-to-excellent results of increased breast-size, a smoother contour for the breast hemisphere, and anatomic symmetry; however, such a breast augmentation might ripple and wrinkle the skin envelope of the breast, cosmetic defects that make noticeable the presence of the prosthetic breast to the eye and to the touch. Such cosmetic defects of the breast surgery usually occur among women with a small volume of adipose tissue in their breast hemispheres.
In the eyes, background retinopathy, proliferative retinopathy, vitreous haemorrhages, and retinal detachments can result in blindness. During pregnancy, intrauterine growth restriction, spontaneous abortion, and pre-eclampsia Chronic pain: Even in the absence of acute vaso-occlusive pain, many patients have unreported chronic pain. Pulmonary hypertension (increased pressure on the pulmonary artery) can lead to strain on the right ventricle and a risk of heart failure; typical symptoms are shortness of breath, decreased exercise tolerance, and episodes of syncope. Evidence of pulmonary hypertension is found in 21% of children and 30% of adults when tested; this is associated with reduced walking distance and increased mortality. Diastolic dysfunction in the left ventricle and cardiomyopathy, caused by fibrosis or scarring of cardiac tissues. This also contributes to pulmonary hypertension, decreased exercise capacity, and arrhythmias.
However, it may have been for religious reasons, and would coincide with the development of religious practices thought to have occurred during the Upper Paleolithic. Nonetheless, it remains possible that Paleolithic societies never practiced cannibalism, and that the damage to recovered human bones was either the result of excarnation or predation by carnivores such as saber-toothed cats, lions, and hyenas. A modern-day diet known as the Paleolithic diet exists, based on restricting consumption only to those foods presumed to be available to anatomically modern humans prior to the advent of settled agriculture.
Sources: en.wikipedia.org
Robert E Synovec (born 1959) is an American analytical chemist and professor of chemistry at the University of Washington where he specializes in multidimensional separations and chemometrics. Synovec has received several awards for his contributions to analytical chemistry and separation science, including the GC×GC Scientific Achievement Award and the Marcel E Golay Award, which is given for recognition of a lifetime of achievement in capillary chromatography.
Lebanese Christians and Druze became a genetic isolate in the predominantly Islamic world. The Druzite and Maronite community in Lebanon played an important role in the formation of the modern state of Lebanon. Contact between Christians (members of the Maronite, Eastern Orthodox, Melkite, and other churches) and the Unitarian Druze led to the presence of mixed villages and towns in Mount Lebanon (Aley District, Baabda District, and Chouf District), Rashaya District, Hasbaya, Matn District, and Marjeyoun District. The relationship between the Druze and Christians in Lebanon has been characterized by harmony and coexistence, and they lived in the Shuf Mountains in the past in complete harmony. Historian Ray Jabre Mouawad observes that there was religious symbiosis between the Druze and Christians in Mount Lebanon during the Ottoman period. Numerous cultural interactions took place in Mount Lebanon, resulting overlapped symbolism, veneration of common saints, and the use of common terminology to refer to God. Traces of these interactions can be found in the palaces and mausoleums of Druze lords, as well as in Maronite and Greek Orthodox churches. Druze and Christians in Lebanon engage in mutual celebrations, including births, weddings, funerals, and religious festivities such as Christmas, Maundy Thursday and Easter. These traditions of sharing and celebration persisted both before and after Lebanese Civil War.
=== Post-marketing drug safety monitoring === The widely publicized recall of Vioxx, a non-steroidal anti-inflammatory drug (NSAID) now estimated to have contributed to fatal heart attacks in thousands of Americans, played a strong role in driving a new wave of safety reforms at both the FDA rulemaking and statutory levels. The FDA approved Vioxx in 1999, and initially hoped it would be safer than previous NSAIDs due to its reduced risk of intestinal tract bleeding. However, a number of pre and post-marketing studies suggested that Vioxx might increase the risk of myocardial infarction, and results from the APPROVe trial in 2004 conclusively demonstrated this. Faced with numerous lawsuits, the manufacturer voluntarily withdrew it from the market. The example of Vioxx has been prominent in an ongoing debate over whether new drugs should be evaluated on the basis of their absolute safety, or their safety relative to existing treatments for a given condition. In the wake of the Vioxx recall, there were widespread calls by major newspapers, medical journals, consumer advocacy organizations, lawmakers, and FDA officials for reforms in the FDA's procedures for pre- and post-market drug safety regulation. In 2006, a Congressional committee was appointed by the Institute of Medicine to review pharmaceutical safety regulation in the U.S. and to issue recommendations for improvements.
where subscripts p and n stand for the proton and neutron, and g(l)n = 0. By using the same identities as here and using the value g(l)p = 1, one gets the following result, in units of the nuclear magneton μN
Sources: en.wikipedia.org
As of 2021, the drug epidemic in the United States was the deadliest it had ever been, according to federal data. More than 100,000 people died of drug overdoses in the United States during the 12-month period ending April 2021, according to provisional data published November 17, 2021, by the US Centers for Disease Control and Prevention. Overdose deaths increased 28.5% from the same period a year earlier and nearly doubled over the previous five years. Opioids continued to be the primary cause of drug overdose deaths. Additionally, the drug is increasingly affecting younger populations. A 2018 study found that fentanyl is involved in the majority of opioid-related deaths and that deaths involving fentanyl were more likely to occur in younger age groups and among non-Hispanic white individuals. Furthermore, young adults are increasingly affected by nonfatal fentanyl overdoses in recent time periods along with these other deadly occurrences. The drug is 50 to 100 times stronger than morphine and often cut with other drugs, meaning the user does not know they are taking fentanyl. The Drug Enforcement Administration (DEA) says 2.2 pounds represents half a million lethal doses. Synthetic opioids, primarily fentanyl, caused nearly two-thirds (64%) of all drug overdose deaths in the 12-month period ending April 2021, up 49% from the year before, the CDC's 's National Center for Health Statistics found. Fentanyl, a synthetic opioid painkiller, is 50 to 100 times more potent than morphine and 30 to 50 times more potent than heroin, with only 2 mg becoming a lethal dose.
== External links == Understanding Gilbert's Syndrome and living better with Gilbert's Syndrome symptoms Gilbert's syndrome at NIH's Office of Rare Diseases Gilbert's Syndrome Archived 2016-05-18 at the Wayback Machine BMJ Best Practices monograph
==== The possibility of using two mixtures in the synthesis ==== In principle, the use of two mixtures in the S&P synthesis can lead to the same combinatorial library that forms in the usual S&P method. The differences in the reactivity of BBs however, bring about large differences in the concentrations of components, and the differences are expected to increase after each step. Although a considerable amount of labor could be saved by using the two mixtures approach when a high number of BBs are coupled in each position, it is advisable to stick to the normally used S&P procedure.
Fu's Subcutaneous Needle (FSN), invented by Dr. Zhonghua Fu in 1996, is a method for the treatment of myofascial pain and trigger points related to Traditional Chinese Medicine (TCM) and invented by Dr. D. Simons and Dr. Janet G. Travell. FSN does not follow the rules and principles of TCM and the chosen insertion points do not coincide with traditional acupuncture points. The similarities are limited to the distal insertion of the needle to the affected area, the needle itself being a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue. FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies. FSN is also currently being used to treat non-musculoskeletal conditions; however more research is to be carried out to conclude its effectiveness.
===== Type 2N (Normandy) ===== Type 2N VWD results from a loss-of-function mutation that reduces the binding of von Willebrand factor (VWF) to factor VIII. Although VWF antigen (quantity) and activity levels (Ristocetin cofactor assay) remain normal, factor VIII levels are typically low (usually 5-15%) due to impaired VWF binding. This vulnerability to proteolysis in the circulation leads to clinical manifestations resembling those of Hemophilia A. The significantly reduced factor VIII levels in VWD Type 2N can sometimes lead to misdiagnosis as mild Hemophilia A. Like Hemophilia A, VWD Type 2N presents with joint and soft tissue bleeds. It is an autosomal recessive disorder, requiring either homozygosity or double heterozygosity for disease manifestation. Diagnostic tools include assessing the ratio of VWF binding to VWF antigen levels. A ratio <0.3 indicates homozygous or double heterozygous VWD Type 2N, while a ratio <0.5 suggests heterozygous VWD Type 2N. Conversely, a VWF antigen-to-binding ratio >3 confirms the diagnosis of VWD Type 2N. Ristocetin-Induced Platelet Agglutination (RIPA) and VWF multimer analysis are typically normal.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.